Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $206.00 at Citigroup

Krystal Biotech (NASDAQ:KRYS) had its price target hoisted by Citigroup from $204.00 to $206.00 in a research note issued to investors on Tuesday morning, Benzinga reports. Citigroup currently has a neutral rating on the stock.

A number of other equities research analysts have also recently commented on the stock. Evercore ISI lifted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Tuesday. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Stifel Nicolaus upped their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Finally, Chardan Capital boosted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Krystal Biotech has an average rating of “Buy” and an average price target of $197.00.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $174.41 on Tuesday. The company has a market capitalization of $5.01 billion, a PE ratio of 98.54 and a beta of 0.82. Krystal Biotech has a 1 year low of $93.95 and a 1 year high of $219.34. The business has a fifty day moving average price of $181.81 and a two-hundred day moving average price of $180.23.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The company’s revenue for the quarter was up 879.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.67) earnings per share. Sell-side analysts anticipate that Krystal Biotech will post 2.88 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in KRYS. EFG Asset Management North America Corp. increased its position in shares of Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after purchasing an additional 60 shares during the last quarter. GAMMA Investing LLC raised its position in Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares during the period. Nisa Investment Advisors LLC lifted its stake in Krystal Biotech by 11.1% in the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after purchasing an additional 94 shares during the last quarter. Arizona State Retirement System boosted its position in Krystal Biotech by 2.1% during the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock valued at $945,000 after buying an additional 108 shares during the period. Finally, Fiera Capital Corp grew its stake in shares of Krystal Biotech by 0.8% during the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock valued at $2,976,000 after buying an additional 130 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).